Trial Profile
Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 27 Sep 2019 Results published in the Clinical Infectious Diseases
- 07 Mar 2018 Results (n=9) assessing concentrations of Tenofovir alafenamide, elvitegravir and tenofovir in CSF in patients who Switch to E/C/F/TAF, presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 22 May 2017 Status changed from active, no longer recruiting to completed.